Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus (SAMS)
Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Macquarie Park, Australia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Vienna, Austria
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Diegem, Belgium
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Sao Paulo, Brazil
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Laval, Canada
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Santiago, Chile
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Santafe de Bogota, Colombia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Praha, Czech Republic
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Berlin, Germany
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Causeway Bay, Hong Kong
- Anofi-Aventis Administrative Office
-
-
-
-
-
Mumbai, India
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Milano, Italy
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Kuala Lumpur, Malaysia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Mexico, Mexico
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Moscow, Russian Federation
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Singapore, Singapore
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Midrand, South Africa
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Barcelona, Spain
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Istanbul, Turkey
- Sanofi-Aventis Administrative Office
-
-
-
-
Surrey
-
Guildford, Surrey, United Kingdom
- Sanofi-Aventis Administrative Office
-
-
-
-
New Jersey
-
Bridgewater, New Jersey, United States, 08807
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria
- Disturbances of sleep maintenance criteria based on participant's information related to sleep pattern during the preceding month
Sub-study :
- Participants will be included if they have an established medical diagnosis of type II Diabetes Mellitus, and have been treated either with an oral hypoglycemic agent and/or insulin for at least three months prior to the Screening Visit (with stable regimen for at least one month prior to screening)
Exclusion Criteria:
- Females who are lactating or who are pregnant
- Night shift workers, and individuals who nap 3 or more times per week over the preceding month
- Consumption of xanthine-containing beverages (i.e. tea, coffee, cola) comprising more than 5 cups/day
- Participation in another trial having received study medication within 1 month before the screening visit
- Body Mass Index ≥ 33
- Use of over-the-counter medications such as tryptophan, valerian root, kava, melatonin, St. John's Wort, Alluna or prescription sleep medication
- Use of any substance with psychotropic effects or properties know to affect sleep/wake
- History of primary hypersomnia, narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, parasomnia, dyssomnia
- Clinically significant, severe or unstable, acute or chronically progressive medical or surgical disorder
- Positive qualitative urine drug screen (opiates, cocaine, amphetamine…)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
oral administration
|
|
EXPERIMENTAL: Volinanserin
|
oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy: change from baseline for Sleep Maintenance Insomnia using patient reported Wake After Sleep Onset (pr-WASO)
Time Frame: at 3 months
|
at 3 months
|
|
Efficacy (sub-study): change from baseline for glycemic measure HbA1c
Time Frame: at 6 and 12 months
|
at 6 and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy: change from baseline of the pr-WASO
Time Frame: at 6 and 12 months
|
at 6 and 12 months
|
|
Efficacy: change from baseline of "General Productivity" domain score of the Functional Outcomes of Sleep Questionnaire
Time Frame: at 3 months
|
at 3 months
|
|
Safety: adverse events and laboratory abnormalities
Time Frame: during 12 months of treatment
|
during 12 months of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Serotonin Agents
- Serotonin Antagonists
- Volinanserin
Other Study ID Numbers
Other Study ID Numbers
- LTE6673
- EudraCT : 2006-004942-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.